Activation of the glucagon-like peptide 1 (GLP-1 ... Semaglutide is a GLP-1 receptor agonist that has been approved by the US Food and Drug Administration and is currently marketed in various dosage ...

Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a ...

Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.

Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal Therapy SHANGHAI, June 2 ...

Mumbai: Novo Nordisk, a global healthcare company headquartered in Denmark, has announced the launch of Wegovy (injectable ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Even after dropping 1,300 bills to focus on the budget, the Florida Legislature passed more than 100 new laws that start July ...

Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...